Thermo Fisher Scientific Inc. Fourth Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Thermo Fisher Scientific, Inc. (NYSE:TMO) will unveil its latest earnings on Wednesday, February 1, 2012. Thermo Fisher Scientific develops, manufactures and sells products to assist the pharmaceutical, biotechnology, academic, government and other research and industrial markets.

Thermo Fisher Scientific, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of $1.15 per share, a rise of 15% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.16. Between one and three months ago, the average estimate was unchanged. It has since dropped over the last month. For the year, analysts are projecting profit of $4.13 per share, a rise of 15.7% from last year.

Past Earnings Performance: Last quarter, the company saw net income of $1.07 per share versus a mean estimate of profit of $1.07 per share. This comes after two consecutive quarters of exceeding expectations.

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

Wall St. Revenue Expectations: On average, analysts predict $3.08 billion in revenue this quarter, a rise of 10.8% from the year ago quarter. Analysts are forecasting total revenue of $11.66 billion for the year, a rise of 8.1% from last year’s revenue of $10.79 billion.

Analyst Ratings: Analysts are bullish on this stock with 14 analysts rating it as a buy, none rating it as a sell and two rating it as a hold.

A Look Back: In the third quarter, profit fell 1.2% to $265.4 million (69 cents a share) from $268.5 million (66 cents a share) the year earlier, meeting analyst expectations. Revenue rose 10.8% to $2.97 billion from $2.68 billion.

Key Stats:

The decrease in profit in the third quarter broke a streak of three consecutive quarters of year-over-year profit increases. Net income rose more than twofold in the second quarter, 8.6% in the first quarter and 8.9% in the fourth quarter of the last fiscal year.

Revenue has gone up for three straight quarters. It rose 9.4% in the second quarter from the year earlier and 1.7% in the first quarter.

Competitors to Watch: PerkinElmer, Inc. (NYSE:PKI), Becton, Dickinson and Co. (NYSE:BDX), Bruker Corporation (NASDAQ:BRKR), Beckman Coulter, Inc. (NYSE:BEC), Harvard Bioscience, Inc. (NASDAQ:HBIO), Bio-Rad Laboratories, Inc. (NYSE:BIO), CareFusion Corporation (NYSE:CFN), Waters Corporation (NYSE:WAT), Teleflex Incorporated (NYSE:TFX), and Quidel Corporation (NASDAQ:QDEL).

Stock Price Performance: During December 27, 2011 to January 26, 2012, the stock price had risen $6.81 (15%) from $45.50 to $52.31. The stock price saw one of its best stretches over the last year between May 5, 2011 and May 16, 2011 when shares rose for eight-straight days, rising 4.3% (+$2.59) over that span. It saw one of its worst periods between March 11, 2011 and March 18, 2011 when shares fell for six-straight days, falling 4.8% (-$2.67) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?